Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
Authors:
- The LonDownS ConsortiumTCThe LonDownS Consortium
- Andre StrydomASAndre Strydom
- Amanda HeslegraveAHAmanda Heslegrave
- Carla M. StartinCSCarla M. Startin
- Kin Y. MokKMKin Y. Mok
Open Access
- 10 April 2018
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 10 (1) , 39
Abstract
Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. A potential biomarker is neurofilament light (NF-L), due to its association with axonal damage in neurodegenerative conditions. We measured blood NF-L concentrations in 100 adults with DS using Simoa NF-light® assays, and we examined relationships with age as well as cross-sectional and longitudinal dementia diagnosis. NF-L concentrations increased with age (Spearman’s rho = 0.789, p < 0.001), with a steep increase after age 40, and they were predictive of dementia status (p = 0.022 adjusting for age, sex, and APOE4), but they showed no relationship with long-standing epilepsy or premorbid ability. Baseline NF-L concentrations were associated with longitudinal dementia status. NF-L is a biomarker for neurodegeneration in DS with potential for use in future clinical trials to prevent or delay dementia.Keywords
All Related Versions
Funding Information
- Wellcome (098330/Z/12/Z)
This publication has 22 references indexed in Scilit:
- Serum neurofilament light in familial Alzheimer diseaseNeurology, 2017
- Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimodMultiple Sclerosis Journal, 2017
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnnals of Neurology, 2017
- The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndromeWellcome Open Research, 2016
- Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementiaNeurology, 2016
- An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluationAlzheimer's & Dementia, 2016
- Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative DiseasesNeuron, 2016
- A genetic cause of Alzheimer disease: mechanistic insights from Down syndromeNature Reviews Neuroscience, 2015
- The relationship of dementia prevalence in older adults with intellectual disability (ID) to age and severity of IDPsychological Medicine, 2008
- The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndromeJournal of Intellectual Disability Research, 2004